Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
AIDS and HIV
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - AIDS and HIV
    ACP Recommends HIV Screening for All Patients, Regardless of Risk Factors - (DGNews)
    FDA Grants Full Approval of Maraviroc for Treatment-Experienced Patients With HIV - (DGNews)
    TopAbstracts in AIDS and HIV 11/24/2008 - (DGNews)
    Early Antiretroviral Therapy and Mortality among HIV-Infected Infants - (N Engl J Med)
    Percutaneous Coronary Intervention Safe in Patients Infected With HIV: Presented at AHA - (DGDispatch)

    News archive

     Recent webcasts/CME - AIDS and HIV

    Webcasts/CME archive

     Recent cases - AIDS and HIV
      Soft Tissue Non-Hodgkin Lymphoma of Shoulder in a HIV Patient: A Report of a Case and Review of the Literature
      HIV, Visceral Leishmaniasis and Parkinsonism Combined with Diabetes Mellitus and Hyperuricaemia: A Case Report
      Primary Kaposi Sarcoma of the Subcutaneous Tissue
      Primary Malignant Melanoma of the Esophagus With Separate Foci of Melanoma In Situ and Atypical Melanocytic Hyperplasia in a Patient Positive for Human Immunodeficiency Virus: A Case Report and Review of the Literature
      HIV-2 Diagnosis and Quantification in High-Risk Patients

      Cases archive
        




      my personal edition > aids and hiv > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      Guidelines Suggest Earlier Treatment for HIV-Infected Patients: Presented at AIDS 2008

        By Ed Susman

        MEXICO CITY -- August 4, 2008 -- Earlier initiation of therapy is warranted for the treatment of human immunodeficiency virus (HIV), before the CD4-positive cell count falls below 350 cells/mcL, according to new guidelines presented here at the 17th International AIDS Conference (AIDS 2008).

        "We have eliminated the upper threshold for initiating treatment … with these new recommendations," said Scott Hammer, MD, Columbia University, New York, New York. Dr. Hammer presented the 2008 Recommendations of the International AIDS Society-USA Panel here on August 3 at a media briefing held by the Journal of the American Medical Association (JAMA). "Previously we had indicated that if a person with HIV infection had a CD4-positive cell count around 500 cells/mcL, then treatment was probably not necessary."

        The recommendations suggest starting therapy with an efavirenz-based therapy or a protease inhibitor/ritonavir-boosted therapy. The backbone of the combination therapy should be tenofovir plus emtricitabine or a combination of abacavir and lamivudine if the patient is infected with a susceptible strain of virus, the panel stated. If the abacavir/lamivudine regimen is preferred, clinicians should perform the genetic susceptibility test HLA-B*5701 to rule out possible reactions to abacavir.

        The recommendations also suggest that doctors change regimens if a patient is intolerant to the medications selected, if there is toxicity to the regimen, or if the regimen fails to maintain viral suppression below the level of detection using the more stringent threshold of less than 50 copies/mL.

        "We should be aiming to reduce the virus levels to below 50 copies/mL, even among patients for whom resistance to an original or subsequent regimen has emerged," Dr. Hammer stated.

        Options have improved to the point that accomplishing that level of viral suppression can be achieved, Dr. Hammer concluded, adding that treatment options have been enhanced with the approval of the integrase strand inhibitor raltegravir, the CCR5-antagonist maraviroc, and second-generation non-nucleoside reverse transcriptase inhibitor etravirine.

        The recommendations are aimed at community settings where state-of-the-art medications are available and accessible.

        The new guidelines will be published this week in the HIV/AIDS-themed issue of JAMA on August 6, 2008. They were developed over the past 2 years through consultations among 14 panel members who reviewed research to arrive at their conclusions.


        [Presentation title: Antiretroviral Treatment of Adult HIV Infection: 2008 Recommendations of the International AIDS Society-USA Panel.]




      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send